These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 25756508)

  • 21. Abiraterone acetate and prednisolone for metastatic castration-resistant prostate cancer failing androgen deprivation and docetaxel-based chemotherapy: a phase II bridging study in Korean and Taiwanese patients.
    Kwak C; Wu TT; Lee HM; Wu HC; Hong SJ; Ou YC; Byun SS; Rhim HY; Kheoh T; Wan Y; Yeh H; Yu MK; Kim CS
    Int J Urol; 2014 Dec; 21(12):1239-44. PubMed ID: 25099185
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Predictive factor analysis of time to progression of castration-resistant prostate cancer after androgen deprivation therapy].
    Ji GJ; Huang C; Song G; Li XS; Song Y; Zhou LQ
    Beijing Da Xue Xue Bao Yi Xue Ban; 2017 Aug; 49(4):657-662. PubMed ID: 28816284
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sargramostim (GM-CSF) and lenalidomide in castration-resistant prostate cancer (CRPC): results from a phase I-II clinical trial.
    Garcia JA; Elson P; Tyler A; Triozzi P; Dreicer R
    Urol Oncol; 2014 Jan; 32(1):33.e11-7. PubMed ID: 23510862
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Smith M; Parker C; Saad F; Miller K; Tombal B; Ng QS; Boegemann M; Matveev V; Piulats JM; Zucca LE; Karyakin O; Kimura G; Matsubara N; Nahas WC; Nolè F; Rosenbaum E; Heidenreich A; Kakehi Y; Zhang A; Krissel H; Teufel M; Shen J; Wagner V; Higano C
    Lancet Oncol; 2019 Mar; 20(3):408-419. PubMed ID: 30738780
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase III, randomized, double-blind, multicenter trial comparing orteronel (TAK-700) plus prednisone with placebo plus prednisone in patients with metastatic castration-resistant prostate cancer that has progressed during or after docetaxel-based therapy: ELM-PC 5.
    Fizazi K; Jones R; Oudard S; Efstathiou E; Saad F; de Wit R; De Bono J; Cruz FM; Fountzilas G; Ulys A; Carcano F; Agarwal N; Agus D; Bellmunt J; Petrylak DP; Lee SY; Webb IJ; Tejura B; Borgstein N; Dreicer R
    J Clin Oncol; 2015 Mar; 33(7):723-31. PubMed ID: 25624429
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Role of PCA 3 as a Prognostic Factor in Patients with Castration-resistant Prostate Cancer (CRPC) Treated with Docetaxel.
    Bourdoumis A; Chrisofos M; Stasinou T; Christopoulos P; Mourmouris P; Kostakopoulos A; Deliveliotis C
    Anticancer Res; 2015 May; 35(5):3075-9. PubMed ID: 25964598
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A randomized phase 2 study of a HSP27 targeting antisense, apatorsen with prednisone versus prednisone alone, in patients with metastatic castration resistant prostate cancer.
    Yu EY; Ellard SL; Hotte SJ; Gingerich JR; Joshua AM; Gleave ME; Chi KN
    Invest New Drugs; 2018 Apr; 36(2):278-287. PubMed ID: 29250742
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prostate-specific antigen kinetics and outcomes in patients with bone metastases from castration-resistant prostate cancer treated with or without zoledronic acid.
    Saad F; Segal S; Eastham J
    Eur Urol; 2014 Jan; 65(1):146-53. PubMed ID: 22633317
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy of metronomic oral cyclophosphamide with low dose dexamethasone and celecoxib in metastatic castration-resistant prostate cancer.
    Jeong Y; Lee JL
    Asia Pac J Clin Oncol; 2017 Jun; 13(3):204-211. PubMed ID: 27521286
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Beyond PSA: managing modern therapeutic options in metastatic castration-resistant prostate cancer.
    Karzai FH; Madan RA; Figg WD
    South Med J; 2015 Apr; 108(4):224-8. PubMed ID: 25871992
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Exponential rise in prostate-specific antigen (PSA) during anti-androgen withdrawal predicts PSA flare after docetaxel chemotherapy in patients with castration-resistant prostate cancer.
    Han KS; Hong SJ
    Yonsei Med J; 2015 Mar; 56(2):368-74. PubMed ID: 25683983
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trial.
    Fizazi K; Massard C; Bono P; Jones R; Kataja V; James N; Garcia JA; Protheroe A; Tammela TL; Elliott T; Mattila L; Aspegren J; Vuorela A; Langmuir P; Mustonen M;
    Lancet Oncol; 2014 Aug; 15(9):975-85. PubMed ID: 24974051
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Therapeutic Effect of Ethinylestradiol in Castration-resistant Prostate Cancer.
    Nakano T; Kadono Y; Iwamoto H; Yaegashi H; Iijima M; Kawaguchi S; Nohara T; Shigehara K; Izumi K; Mizokami A
    Anticancer Res; 2020 Apr; 40(4):2291-2296. PubMed ID: 32234928
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Major response to cyclophosphamide and prednisone in recurrent castration-resistant prostate cancer.
    Batty N; Yarlagadda N; Pili R
    J Natl Compr Canc Netw; 2013 Aug; 11(8):911-5. PubMed ID: 23946170
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Metronomic chemotherapy with cyclophosphamide plus low dose of corticosteroids in advanced castration-resistant prostate cancer across the era of taxanes and new hormonal drugs.
    Calvani N; Morelli F; Naglieri E; Gnoni A; Chiuri VE; Orlando L; Fedele P; Cinieri S
    Med Oncol; 2019 Aug; 36(9):80. PubMed ID: 31399784
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Everolimus combined with gefitinib in patients with metastatic castration-resistant prostate cancer: Phase 1/2 results and signaling pathway implications.
    Rathkopf DE; Larson SM; Anand A; Morris MJ; Slovin SF; Shaffer DR; Heller G; Carver B; Rosen N; Scher HI
    Cancer; 2015 Nov; 121(21):3853-61. PubMed ID: 26178426
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The New Combination Docetaxel, Prednisone and Curcumin in Patients with Castration-Resistant Prostate Cancer: A Pilot Phase II Study.
    Mahammedi H; Planchat E; Pouget M; Durando X; Curé H; Guy L; Van-Praagh I; Savareux L; Atger M; Bayet-Robert M; Gadea E; Abrial C; Thivat E; Chollet P; Eymard JC
    Oncology; 2016; 90(2):69-78. PubMed ID: 26771576
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety and Antitumour Activity of ODM-201 (BAY-1841788) in Castration-resistant, CYP17 Inhibitor-naïve Prostate Cancer: Results from Extended Follow-up of the ARADES Trial.
    Fizazi K; Massard C; Bono P; Kataja V; James N; Tammela TL; Joensuu H; Aspegren J; Mustonen M
    Eur Urol Focus; 2017 Dec; 3(6):606-614. PubMed ID: 28753849
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Bipolar androgen therapy: A novel therapeutic strategy for castration-resistant prostate cancer].
    Hu YH; Guo JC; Zhang M
    Zhonghua Nan Ke Xue; 2017 Dec; 23(12):1138-1140. PubMed ID: 29738189
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prior Endocrine Therapy Impact on Abiraterone Acetate Clinical Efficacy in Metastatic Castration-resistant Prostate Cancer: Post-hoc Analysis of Randomised Phase 3 Studies.
    Bellmunt J; Kheoh T; Yu MK; Smith MR; Small EJ; Mulders PF; Fizazi K; Rathkopf DE; Saad F; Scher HI; Taplin ME; Davis ID; Schrijvers D; Protheroe A; Molina A; De Porre P; Griffin TW; de Bono JS; Ryan CJ; Oudard S
    Eur Urol; 2016 May; 69(5):924-32. PubMed ID: 26508309
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.